To further explore whether EXOSC5 could promote proliferation of GC via AKT and STAT3 signaling pathways, the EXOSC5 overexpression MKN45 were treated by the AKT inhibitor MK-2206 or STAT3 inhibitor S31-201. Here, STAT3 is linked to gastric cancer.